Bcal Diagnostics Limited · ASX:BDX
Bcal Diagnostics — H1 FY2026 Earnings Presentation
18 slides from Bcal Diagnostics's earnings presentation, February 2026
Slide 1: Half Year 2026 Results
Half Year 2026 Results Executive Chair Jayne Shaw Chief Executive Officer Shane Ryan February 2026
Slide 2: 1H FY26 Highlights
1H FY26 Highlights Continue product development and progressing commercialisation BREASTESTplus Avantect ® Pancreatic & Ovarian Strengthened balance sheet • 215 tests sold in 1H FY26 • Secured exclusive ANZ licence for • Established $10 million Convertible ClearNote Health’s Avantect® Note facility
Slide 3: 1H FY26 Results
1H FY26 Results • Lower research and development tax A$000’s 1H FY26 1H FY25 offset in 1H FY26 Revenue 1,273 1,385 • Initial revenues from BREASTESTplusTM Product Sales 43 - Net Loss After Tax (3,917) (3,999) • Ongoing investment in R&D to deliver Key Cost Drivers version II of BREASTESTplusTM R&D (
Slide 4: BREASTESTplus
BREASTESTplus Now available in 20 clinics, supported by 90 doctors and 93 1 pathology sites across NSW. Version 2 of BREASTESTplus in development, with focus on 2 increasing test performance and enhancing clinical utility. Ongoing doctor education programs to support evidence- 3 based use and influe
Slide 5: Avantect Pancreatic & Ovarian
Avantect ® Pancreatic & 1,000 registered enquiries, 60 bookings, and 30 tests completed during first ten days following launch at the Sydney Breast Clinic. Ovarian 12 ovarian screening centres scheduled to commence onboarding during February World-first early detect blood tests for Unit test price o
Slide 6: BCAL 1H FY26 Results Investor Presentation
BCAL 1H FY26 Results Investor Presentation 6
Slide 7: 2026 milestones
2026 milestones Q1 Q2 Q3 Q4 Expand BREASTESTplus footprint across Melbourne and Brisbane; initiate regional rollout program Sydney market launch of Avantect® Ovarian and Pancreatic tests BREASTESTplus incorporated into Best Practice GP management software - national Two publications on BREASTESTplus
Slide 8: Reimbursement strategy for Avantect
Reimbursement strategy for Avantect MSAC Pathway Feb 26 Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan 27 Feb Mar Apr May Jun Jul Aug Sep Define Service & PICO Pre-App MSAC Engagement SoCR & Regulatory Prep MSAC Application Lodgement Pre-Assessment & PASC Assessment Report (ADAR) ESC Review & Response
Slide 9: Pancreatic & Ovarian roll out strategy
Pancreatic & Ovarian roll out strategy Leveraging established BREASTESTplusTM network Sydney Melbourne Noosa National 19 January 9 February 23 February 3 March Sydney Breast Clinic Southern Breast Oncology Cancer Care Associates Helius Laboratory: national collection Sonic Health: national agreement
Slide 10: The clinical pathway for novel oncology
SCALE The clinical NATIONWIDE pathway for novel 5 oncology • Expand across oncology GENERATE REAL- networks, breast clinics, and WORLD general practice biomarkers in EVIDENCE • Harness clinician 4 recommendations and Australia patient demand to reach late • Collect and share clinical LEVERAGE EARLY
Slide 11: Addressing high-growth global markets in cancer diagnostics
Addressing high -growth global markets in cancer diagnostics Breast cancer 8% CAGR reaching $40.7B by 2034* US$20.1B1 Pancreatic cancer 7.2% CAGR US$4B2 Ovarian cancer 6.6% CAGR US$1.9B3 1Breast Cancer Diagnostics Market Size, Share, and Trends 2025 to 2034, https://www.precedenceresearch.com/breast
Slide 12: Advocacy & clinical partners
Advocacy & clinical partners BCAL 1H FY26 Results Investor Presentation 12
Slide 13: Building the clinical advisory board for pancreatic and ovarian cancer
Building the clinical advisory board for pancreatic and ovarian cancer Prof. Jas Samra Prof. Steve Robson Dr. Greg Gard • One of Australia’s most experienced pancreatic • Australia’s foremost advocate for pancreatic • Certified gynaecological oncologist surgeons. cancer diagnosis and treatment. • Se
Slide 14: Expert breast cancer clinical advisory board
Expert breast cancer clinical advisory board Dr David Speakman OAM Prof Bruce Mann Dr Corinne Ooi A/Prof. James French Prof. Elisabeth Elder Chair Clinical Advisory Director of Breast Cancer Head of the Monash Health Head of Breast Surgery Head of Research at the Board Services for the Royal Breast
Slide 15: BCAL investment summary
BCAL investment summary Commercialised Large & growing Strategic Strong R&D Experienced breakthrough global markets partnerships & pipeline and IP leadership technology expansion First-in-class, clinically Addressing significant Licensing agreement BREASTEST plus Establishing track validated blood t
Slide 16: Outlook
Outlook For the remainder of FY2026 BCAL is focussed on the following. Progressing commercial deliverables under the ClearNote Health partnership following the launch of new 1 cancer tests in January 2026. Delivery of an updated version of BREASTESTplus with a launch target of June 2026, aiming to d
Slide 17: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by BCAL Diagnostics The forward-looking statements are based on information available to BCAL Not An Offer Ltd ABN 51 142 051 223 (BCAL or the Company). as at the date of this Presentation. Circumstances may change and the This P re s e n
Slide 18: Thank you.
Thank you. Pancreatic cancer 7.2% CAGR For further Information Ovarian cancer Jayne Shaw Shane Ryan Executive Chair Chief Executive Officer Jshaw@bcaldiagnostics.com Sryan@bcaldiagnostics.com